ArticleCanadian journal of kidney health and disease2025
Autosomal Dominant Polycystic Kidney Disease and Idiopathic Arginine Vasopressin Deficiency: A Peculiar Case Report of Accelerated Kidney Function Decline.
Article in Canadian journal of kidney health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is a common genetic kidney disorder characterized by progressive cyst growth and kidney impairment. Arginine vasopressin deficiency (AVP-D) is a rare disorder resulting from reduced arginine vasopressin production, causing polyuria and thirst. The coexistence of ADPKD and AVP-D is rarely documented in the literature. We report what may be the first documented case of a patient diagnosed with ADPKD and idiopathic AVP-D. Initially managed with intranasal desmopressin, the patient's kidney function declined earlier than expected based on her ADPKD, progressing to kidney failure at a low total kidney volume (836 mL). This paradoxical outcome suggests that while AVP-D may have initially slowed cyst growth, her uncontrolled AVP-D likely contributed to kidney function decline, presumably due to recurrent volume depletion and acute kidney injuries. This case highlights the need for individualized AVP-D management in ADPKD patients and reiterates AVP's role in the complex pathophysiology of ADPKD progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.